CompletedPhase 2NCT01210560

Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

Studying Autosomal dominant polycystic kidney disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Principal Investigator
Frank Czerwiec, M.D., Ph.D.
Otsuka Pharmaceutical Development & Commercialization, Inc.
Intervention
Tolvaptan MR(drug)
Enrollment
25 enrolled
Eligibility
18-50 years · All sexes
Timeline
20102011

Study locations (6)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01210560 on ClinicalTrials.gov

Other trials for Autosomal dominant polycystic kidney disease

Additional recruiting or active studies for the same condition.

See all trials for Autosomal dominant polycystic kidney disease

← Back to all trials